Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Ahlen – page 67

864 clinical trials in Ahlen, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Ahlen at a glance
864
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

864 trials in Ahlen

Open in trial search

Follicular lymphoma+1

Not recruiting

Study of Tafasitamab, Lenalidomide, and Rituximab for Patients with Relapsed or Refractory Follicular or Marginal Zone Lymphoma

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide
  • Sponsor:Incyte Corp.

Major depression

Not recruiting

Study on the Effect of Ketamine and Esketamine in Patients with Major Depressive Disorder After First-Line Treatment Failure

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Agomelatine
  • Sponsor:Universitair Medisch Centrum Utrecht

Study on Ribociclib and Drug Combination for Patients with Advanced HER2-Negative, Hormone Receptor Positive Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Institut Für Frauengesundheit GmbH

Plasma cell myeloma

Not recruiting

Study on Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone for Patients with Newly Diagnosed Low-Risk Multiple Myeloma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Universitaetsklinikum Schleswig-Holstein AöR

Plasma cell myeloma

Not recruiting

Study to Compare Mezigdomide, Carfilzomib, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:Celgene Corp.

Dermatitis atopic+1

Not recruiting

Study on the Effect of a New Moisturiser with Paraffin and Liquid Paraffin on Preventing Eczema Relapse in Children

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Glycerol
  • Sponsor:ACO Hud Nordic AB

Study of Pembrolizumab and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Enzalutamide
  • Sponsor:Merck Sharp & Dohme LLC

Study of LY3473329 for Adults with High Lipoprotein(a) Levels at Risk for Heart Problems

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Muvalaplin
  • Sponsor:Eli Lilly & Co.

Psoriasis

Not recruiting

Study on the Effectiveness and Safety of HRO350 for Patients with Mild-to-Moderate Psoriasis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pehero
  • Sponsor:Arctic Bioscience AS

Oesophageal carcinoma

Not recruiting

Study of Pembrolizumab in Patients with Esophageal Cancer Undergoing Chemoradiotherapy

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Merck Sharp & Dohme LLC

Study of Datopotamab Deruxtecan and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer with Low PD-L1 Levels

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Daiichi Sankyo Inc.

Back pain

Not recruiting

Study on the Effectiveness and Safety of AP707 and Naproxen for Patients with Chronic Back Pain

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Aceclofenac
  • Sponsor:Apurano Pharmaceuticals GmbH

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Ahlen

What the registry says about research in the country

01 Neoplasms (Cancer) Research

In Ahlen, researchers are conducting two recruiting neoadjuvant studies that target HER2+ early breast cancer and triple-negative early breast cancer. The trials compare novel antibody‑drug conjugates with standard chemotherapy regimens, aiming to improve safety profiles and increase pathological complete response rates.

  • Safety profiling of a trastuzumab‑deruxtecan based regimen
  • Efficacy comparison using 3‑year distant disease‑free survival
  • Assessment of sacituzumab govitecan with or without pembrolizumab
  • Evaluation of pathological complete response as a co‑primary endpoint

The single study center in Ahlen enables close coordination between the investigator team and participating patients, fostering rapid enrollment and data collection for these cutting‑edge breast cancer studies.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.